Review

anti parp1 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech anti parp1
Anti Parp1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 834 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+parp1/PARP1+Antibody/pm42901288-93-52-53
Average 96 stars, based on 834 article reviews

anti parp1 - by Bioz Stars, 2026-11

96/100 stars

Images

Immunohistochemistry:

Article Title: PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation
Article Snippet: For immunofluorescence, anti-ProSPC (1:200, no. 10774-1-AP, Proteintech), anti–α-SMA (1:200, no. GB13044-50, Servicebio), and anti-PARP1 (1:200, no. sc-136208). .. For immunohistochemistry, the following antibodies were used: anti-FOXN3 (1:200, no. ab129453, Abcam) and anti-PARP1 (1:200, no. 13371-1-AP, Proteintech). .. For immunoprecipitation (IP), the following antibodies were used: anti-FOXN3 antibody (no. ab129453, Abcam) and anti-rabbit IgG (immunoglobulin G; no. 30000-0-AP, Proteintech).

Article Title: PARP1 stabilizes FOXN3 to suppress pulmonary fibrosis through p38-related feedback regulation.
Article Snippet: For immunofluorescence, anti- ProSPC (1:200, no. 10774- 1- AP, Proteintech), anti–α- SMA (1:200, no. GB13044- 50, Servicebio), and anti- PARP1 (1:200, no. sc- 136208). .. For immunohistochemistry, the following antibodies were used: anti- FOXN3 (1:200, no. ab129453, Abcam) and anti- PARP1 (1:200, no. 13371- 1- AP, Proteintech). .. For immunoprecipitation (IP), the following antibodies were used: anti- FOXN3 antibody (no. ab129453, Abcam) and anti- rabbit IgG (immunoglobulin G; no. 30000- 0- AP, Proteintech).

other:

Article Title: Discovery of selective PARP1/CDK6 dual target inhibitors modulating Wnt signaling pathway for the treatment of TNBC.
Article Snippet: The combination of PARP1 and CDK6 inhibitors shows synergistic anticancer effects in TNBC.. However, firstgeneration PARP inhibitors lack optimal PARP trapping efficiency and enzyme family selectivity, often leading to hematotoxicity.. Herein, we report the rational design and synthesis of a series of second-generation selective PARP1/CDK6 dual inhibitors, based on the structural features of the latest selective PARP1 inhibitor AZD5305.

Western Blot:

Article Title: Enolase 1 inhibition potentiates sorafenib efficacy in hepatocellular carcinoma through ferroptosis induction.
Article Snippet: Enolase 1 (ENO1) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor patient prognosis, as evidenced by TCGA and Kaplan-Meier (KM) analysis.. This study demonstrates that targeting ENO1 with its specific inhibitor, ENOblock, markedly enhances the antitumor efficacy of sorafenib in HCC cells.. The combination of sorafenib and ENOblock significantly suppresses cell proliferation, migration, invasion, and angiogenesis in vitro and in vivo.